

## Gene Section

### Short Communication

# FIGF (c-fos induced growth factor (vascular endothelial growth factor D))

Marina Rocchigiani, Salvatore Oliviero

Department of Molecular Biology, University of Siena, Italy (MR, SO)

Published in Atlas Database: May 2012

Online updated version : <http://AtlasGeneticsOncology.org/Genes/FIGFID40574chXp22.html>

DOI: 10.4267/2042/48228

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.  
© 2012 Atlas of Genetics and Cytogenetics in Oncology and Haematology

### Identity

**Other names:** VEGF-D, VEGFD

**HGNC (Hugo):** FIGF

**Location:** Xp22.2

### DNA/RNA

#### Description

The VEGFD gene consists of 7 exons and spans 38865 bases on chromosome X in minus strand orientation. The upstream promoter sequence does not contain a canonical TATA box.

The promoter sequence contains an optimal AP-1 binding site at position -54 from the start site.

#### Transcription

The mRNA transcribed from this gene is 2110 nucleotides long.

### Protein

#### Description


VEGF-D is a member of the Platelet-Derived


Growth Factor/Vascular Endothelial Growth Factor (PDGF/VEGF) family that contains a conserved domain of eight cysteine residues forming the typical cysteine-knot structure involved in the formation of the biologically active dimer (Debinski et al., 2001; Rocchigiani et al., 1998; Yamada et al., 1997; Joukov et al., 1996).

The human VEGF family consists of 5 members: VEGF-A, VEGF-B, VEGF-C, VEGF-D and Placental Growth Factor (PlGF) which differ in their ability to bind to VEGF receptors that are primarily expressed in endothelial cells: VEGFR1 (Flt1), VEGFR2 (KDR, Flk1), VEGFR3 (Flt4), neuropilin-1 and neuropilin-2. VEGFA binds to VEGFR1, VEGFR2, as well as neuropilin-1 and neuropilin-2, whereas PlGF and VEGFB bind only to VEGFR1 and neuropilin-1.

VEGF-C and VEGF-D, which share 23% amino acid sequence identity, are uniquely expressed as preproteins that contain long N- and C-terminal propeptide extensions around the VEGF homology domain (VHD).

The C-terminal amino acid sequence show a pattern of spacing cysteine residues reminiscent of the BR3P sequence.





The VEGF-D chain is a secreted protein synthesised as 354 amino acid precursor containing a signal peptide (AA:1-21), an N-propeptide (AA:22-88), a VHD (VEGF Homology Domain, AA:89-205) and a C-propeptide (AA:206-354).

Proteolytic processing of the 354 aa VEGF-D preproprotein creates a secreted proprotein. Further processing by extracellular serine proteases, such as plasmin or furin-like proprotein convertases, forms mature VEGF-D consisting of non-covalently linked homodimers of the 117 aa VHD (Stacker et al., 1999; McColl et al., 2003; McColl et al., 2007). Human VEGF-D is ligand for VEGFR-2 and VEGFR-3.

VEGF-D is expressed in fibroblasts and its messenger is stabilized by cell contacts (Orlandini and Oliviero, 2001).

Its receptor VEGFR3 is constitutively expressed in lymphatic endothelial cells and in vascular endothelial cells during angiogenesis and in endothelial precursors and in osteoblasts (Tammela et al., 2011; Orlandini et al., 2006).

VEGF-D and VEGFR-3 are expressed in the osteoblasts of the growing plate.

The treatment of primary human osteoblasts with recombinant VEGF-D induces the expression of

osteocalcin and the formation of mineralized nodules in a dose-dependent manner (Orlandini et al., 2006).

**Expression**

It is expressed in adult lung, heart, muscle, and small intestine, and is most abundantly expressed in fetal lungs and skin.

VEGF-D expression in mouse fibroblasts is induced by cell interaction mediated by cadherin 11 (Orlandini et al., 2006; Avantaggiato et al., 1998).

**Localisation**

Secreted in the extracellular medium.

**Function**

Growth factor active in angiogenesis, lymphangiogenesis and endothelial cell growth, stimulating their proliferation and migration of blood cells. It may function in the formation of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic

endothelium in adults. Binds and activates VEGFR-2 (Flk1) and VEGFR-3 (Flt4) receptors.

VEGFD controls the total length and complexity of dendrites both in cultured hippocampal neurons and in the adult mouse hippocampus (Mauceri et al., 2011).

VEGFD together with SDF1 $\alpha$  and sFRP1 are major components of stromal cell-derived inducing activity of dopaminergic neurons (Schwartz et al., 2012).

### Homology

VEGF-D is highly conserved, it shares 94%, 95%, 99%, 97% and 93% aa identity with mouse, rat, equine, canine and bovine VEGF-D, respectively.

## Mutations

### Note

Single Nucleotide Polymorphism have been described in mRNA UTR, introns or in exons: see NCBI database.

## Implicated in

### Lymphangioliomyomatosis

#### Note

VEGF-D prognostic marker for tumor growth and dissemination.

#### Disease

High level VEGFD in patients with lymphangioliomyomatosis.

#### Prognosis

Serum VEGF-D may be a clinically useful diagnostic test that can distinguish sporadic lymphangioliomyomatosis from other cystic and chylous lung diseases, potentially decreasing the need for lung biopsy (Young et al., 2008).

### Metastasis

#### Note

VEGF-D-dependent regulation of the prostaglandin pathway induces lymphatic vessel dilation and subsequent increase of metastatic spread (Karnezis et al., 2012).

### Soft tissue sarcoma

#### Note

VEGF-D significantly increases the migration of sarcoma cells through lymphatic endothelial monolayers. The VEGF-D-dependent induced migration through lymphatics might be the reason for relationship between VEGF-D expression and lymph node metastasis in soft tissue sarcomas (Yanagawa et al., 2012).

## References

Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kuk E, Saksela O, Kalkkinen N, Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4

(VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. *EMBO J.* 1996 Jan 15;15(2):290-98

Yamada Y, Nezu J, Shimane M, Hirata Y. Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. *Genomics.* 1997 Jun 15;42(3):483-8

Avantaggiato V, Orlandini M, Acampora D, Oliviero S, Simeone A. Embryonic expression pattern of the murine figf gene, a growth factor belonging to platelet-derived growth factor/vascular endothelial growth factor family. *Mech Dev.* 1998 May;73(2):221-4

Rocchigiani M, Lestingi M, Luddi A, Orlandini M, Franco B, Rossi E, Ballabio A, Zuffardi O, Oliviero S. Human FIGF: cloning, gene structure, and mapping to chromosome Xp22.1 between the PIGA and the GRPR genes. *Genomics.* 1998 Jan 15;47(2):207-16

Stacker SA, Stenvers K, Caesar C, Vitali A, Domagala T, Nice E, Roufail S, Simpson RJ, Moritz R, Karpanen T, Alitalo K, Achen MG. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. *J Biol Chem.* 1999 Nov 5;274(45):32127-36

Debinski W, Slagle-Webb B, Achen MG, Stacker SA, Tulchinsky E, Gillespie GY, Gibo DM. VEGF-D is an X-linked/AP-1 regulated putative onco-angiogen in human glioblastoma multiforme. *Mol Med.* 2001 Sep;7(9):598-608

Orlandini M, Oliviero S. In fibroblasts Vegf-D expression is induced by cell-cell contact mediated by cadherin-11. *J Biol Chem.* 2001 Mar 2;276(9):6576-81

McCull BK, Baldwin ME, Roufail S, Freeman C, Moritz RL, Simpson RJ, Alitalo K, Stacker SA, Achen MG. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D. *J Exp Med.* 2003 Sep 15;198(6):863-8

Orlandini M, Spreafico A, Bardelli M, Rocchigiani M, Salameh A, Nucciotti S, Capperucci C, Frediani B, Oliviero S. Vascular endothelial growth factor-D activates VEGFR-3 expressed in osteoblasts inducing their differentiation. *J Biol Chem.* 2006 Jun 30;281(26):17961-7

McCull BK, Paavonen K, Karnezis T, Harris NC, Davydova N, Rothacker J, Nice EC, Harder KW, Roufail S, Hibbs ML, Rogers PA, Alitalo K, Stacker SA, Achen MG. Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2. *FASEB J.* 2007 Apr;21(4):1088-98

Young LR, Inoue Y, McCormack FX. Diagnostic potential of serum VEGF-D for lymphangioliomyomatosis. *N Engl J Med.* 2008 Jan 10;358(2):199-200

Mauceri D, Freitag HE, Oliveira AM, Bengtson CP, Bading H. Nuclear calcium-VEGFD signaling controls maintenance of dendrite arborization necessary for memory formation. *Neuron.* 2011 Jul 14;71(1):117-30

Tammela T, Zarkada G, Nurmi H, Jakobsson L, Heinolainen K, Tvorogov D, Zheng W, Franco CA, Murtomäki A, Aranda E, Miura N, Ylä-Herttuala S, Fruttiger M, Mäkinen T, Eichmann A, Pollard JW, Gerhardt H, Alitalo K. VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling. *Nat Cell Biol.* 2011 Sep 11;13(10):1202-13

Karnezis T, Shayan R, Caesar C, Roufail S, Harris NC, Ardipradja K, Zhang YF, Williams SP, Farnsworth RH, Chai MG, Rupasinghe TW, Tull DL, Baldwin ME, Sloan EK, Fox SB, Achen MG, Stacker SA. VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. *Cancer Cell.* 2012 Feb 14;21(2):181-95

Schwartz CM, Tavakoli T, Jamias C, Park SS, Maudsley S, Martin B, Phillips TM, Yao PJ, Itoh K, Ma W, Rao MS, Arenas

E, Mattson MP. Stromal factors SDF1 $\alpha$ , sFRP1, and VEGFD induce dopaminergic neuron differentiation of human pluripotent stem cells. *J Neurosci Res.* 2012 Jul;90(7):1367-81

Yanagawa T, Shinozaki T, Watanabe H, Saito K, Raz A, Takagishi K. Vascular endothelial growth factor-D is a key molecule that enhances lymphatic metastasis of soft tissue sarcomas. *Exp Cell Res.* 2012 Apr 15;318(7):800-8

---

*This article should be referenced as such:*

Rocchigiani M, Oliviero S. FIGF (c-fos induced growth factor (vascular endothelial growth factor D)). *Atlas Genet Cytogenet Oncol Haematol.* 2012; 16(11):809-812.

---